Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis

Journal of Neuroimmunology

Volumn 280, Issue , 2015, Pages 21-28

  Røsjø, Egil ^a,b   Myhr, Kjell Morten ^c,d   Løken Amsrud, Kristin I ^e   Bakke, Søren J ^f   Beiske, Antonie G ^g   Bjerve, Kristian S ^h,i   Hovdal, Harald ^h   Lilleås, Finn ^j   Midgard, Rune ^i,k   Pedersen, Tom ^l   Šaltyte Benth, Jurate ^a,b   Torkildsen, Øivind ^c,d   Wergeland, Stig ^c   Michelsen, Annika E ^b,f   Aukrust, Pål ^b,f   Ueland, Thor ^b,f   Holmøy, Trygve ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e INNLANDET HOSPITAL TRUST   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g Multiple Sclerosis Centre Hakadal   (Norway)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

ⁱ NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^j Curato Oslo   (Norway)

^k Hospital of Molde   (Norway)

^l Unilabs   (France)

more..

Author keywords

Interferon treatment; Relapsing remitting multiple sclerosis; Vitamin D

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; OMEGA 3 FATTY ACID; PLACEBO; VITAMIN D; BETA INTERFERON; CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; REFERENCE VALUE; SYSTEMIC DISEASE; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN D BLOOD LEVEL; ADOLESCENT; BLOOD; LONGITUDINAL STUDY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NORWAY; PATHOLOGY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TIME; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CYTOKINES; FEMALE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NORWAY; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; VITAMIN D; YOUNG ADULT;

EID: 84924769575     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.02.001     Document Type: Article

References (35)

1. Aarskog N.K., Marøy T., Myhr K.M., Vedeler C.A. Antibodies against interferon-beta in multiple sclerosis. J. Neuroimmunol. 2009, 212(1-2):148-150. (available from: PM:19467718).
2. Ascherio A., Munger K.L., White R., Kochert K., Simon K.C., Polman C.H., Freedman M.S., Hartung H.P., Miller D.H., Montalban X., Edan G., Barkhof F., Pleimes D., Radu E.W., Sandbrink R., Kappos L., Pohl C. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014, 71(3):306-314. (available from: PM:24445558).
3. Autier P., Boniol M., Pizot C., Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014, 2(1):76-89. (available from: PM:24622671).
4. Bayas A., Gold R. Lessons from 10years of interferon beta-1b (Betaferon/Betaseron) treatment. J. Neurol. 2003, 250(Suppl. 4):IV3-IV8. (available from: PM:14712395).
5. Bikle D.D. Vitamin D regulation of immune function. Vitam. Horm. 2011, 86:1-21. (available from: PM:21419265).
6. Breuer J., Schwab N., Schneider-Hohendorf T., Marziniak M., Mohan H., Bhatia U., Gross C.C., Clausen B.E., Weishaupt C., Luger T.A., Meuth S.G., Loser K., Wiendl H. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann. Neurol. 2014, 75(5):739-758. (available from: PM:24771567).
7. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R., Gagne D., D'Souza C., Ursell M., O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74(23):1852-1859. (available from: PM:20427749).
8. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009, 132(Pt 5):1146-1160. (available from: PM:19321461).
9. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24. (available from: PM:20038758).
10. Dorr J., Ohlraun S., Skarabis H., Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012, 13:15. (available from: PM:22316314).
11. Filippini G., Munari L., Incorvaia B., Ebers G.C., Polman C., D'Amico R., Rice G.P. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003, 361(9357):545-552. (available from: PM:12598138).
12. Freedman M.S., Hughes B., Mikol D.D., Bennett R., Cuffel B., Divan V., LaVallee N., Al-Sabbagh A. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur. Neurol. 2008, 60(1):1-11. (available from: PM:18437041).
13. Gal-Tanamy M., Bachmetov L., Ravid A., Koren R., Erman A., Tur-Kaspa R., Zemel R. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011, 54(5):1570-1579. (available from: PM:21793032).
14. Handel A.E., Giovannoni G., Ebers G.C., Ramagopalan S.V. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 2010, 6(3):156-166. (available from: PM:20157307).
15. Holmøy T., Løken-Amsrud K.I., Bakke S.J., Beiske A.G., Bjerve K.S., Hovdal H., Lilleas F., Midgard R., Pedersen T., Saltyte Benth J., Torkildsen Ø., Wergeland S., Myhr K.M., Michelsen A.E., Aukrust P., Ueland T. Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLoS One 2013, 8(9):e75021. (available from: PM:24069377).
16. James E., Dobson R., Kuhle J., Baker D., Giovannoni G., Ramagopalan S.V. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult. Scler. 2013, 19(12):1571-1579. (available from: PM:23698130).
17. Lin R., Taylor B.V., Charlesworth J., van der Mei I., Blizzard L., Stewart N., Ponsonby A.L., Dwyer T., Pittas F., Simpson S. Modulating effects of WT1 on interferon-beta-vitamin D association in MS 2014, Acta Neurol, Scand, (available from: PM:25312909).
18. Løken-Amsrud K.I., Holmøy T., Bakke S.J., Beiske A.G., Bjerve K.S., Bjørnarå B.T., Hovdal H., Lilleas F., Midgard R., Pedersen T., Saltyte Benth J., Sandvik L., Torkildsen Ø., Wergeland S., Myhr K.M. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology 2012, 79(3):267-273. (available from: PM:22700809).
19. Lucas R.M., Ponsonby A.L., Dear K., Valery P.C., Pender M.P., Taylor B.V., Kilpatrick T.J., Dwyer T., Coulthard A., Chapman C., van d.M.I, Williams D., McMichael A.J. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76(6):540-548. (available from: PM:21300969).
20. Mowry E.M., Krupp L.B., Milazzo M., Chabas D., Strober J.B., Belman A.L., McDonald J.C., Oksenberg J.R., Bacchetti P., Waubant E. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann. Neurol. 2010, 67(5):618-624. (available from: PM:20437559).
21. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296(23):2832-2838. (available from: PM:17179460).
22. Munger K.L., KÔchert K., Simon K.C., Kappos L., Polman C., Freedman M.S., Hartung H.P., Miller D.H., Montalban X., Edan G., Barkhof F., Pleimes D., Sandbrink D., Ascherio A., Pohl C. Molecular mechanisms underlying the impact of vitamin D on disease activity of MS. Ann. Clin. Transl. Neurol. 2014, 1(8):605-617.
23. Pierrot-Deseilligny C., Rivaud-Pechoux S., Clerson P., de Paz R., Souberbielle J.C. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther. Adv. Neurol. Disord. 2012, 5(4):187-198. (available from: PM:22783368).
24. Pozuelo-Moyano B., Benito-Leon J., Mitchell A.J., Hernandez-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 2013, 40(3):147-153. (available from: PM:23257784).
25. Røsjø E., Myhr K.M., Løken-Amsrud K.I., Bakke S.J., Beiske A.G., Bjerve K.S., Hovdal H., Lilleas F., Midgard R., Pedersen T., Saltyte Benth J., Torkildsen Ø., Wergeland S., Michelsen A.E., Aukrust P., Ueland T., Holmoy T. Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. J. Neuroimmunol. 2014, 271(1-2):60-65. (available from: PM:24713402).
26. Rotstein D., Healy B., Malik M.T., Carruthers R., Musallam A., Kivisakk P., Glanz B., Chitnis T. Differential effects of vitamin D in GA- versus IFN-treated MS patients. Neurology 2014, 82(10). (P24.005).
27. Sakai S., Takaishi H., Matsuzaki K., Kaneko H., Furukawa M., Miyauchi Y., Shiraishi A., Saito K., Tanaka A., Taniguchi T., Suda T., Miyamoto T., Toyama Y. 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J. Bone Miner. Metab. 2009, 27(6):643-652. (available from: PM:19449179).
28. Saltyte Benth J., Myhr K.M., Løken-Amsrud K.I., Beiske A.G., Bjerve K.S., Hovdal H., Midgard R., Holmøy T. Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology 2012, 39(2):84-93. (available from: PM:22814117).
29. Salzer J., Hallmans G., Nyström M., Stenlund H., Wadell G., Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012, 79(21):2140-2145. (available from: PM:23170011).
30. Simpson S., Taylor B., Blizzard L., Ponsonby A.L., Pittas F., Tremlett H., Dwyer T., Gies P., van der Mei I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 2010, 68(2):193-203. (available from: PM:20695012).
31. Smolders J., Hupperts R., Barkhof F., Grimaldi L.M., Holmøy T., Killestein J., Rieckmann P., Schluep M., Vieth R., Hostalek U., Ghazi-Visser L., Beelke M. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J. Neurol. Sci. 2011, 311(1-2):44-49. (available from: PM:21620416).
32. Soilu-Hänninen M., Aivo J., Lindström B.M., Elovaara I., Sumelahti M.L., Färkkilä M., Tienari P., Atula S., Sarasoja T., Herrala L., Keskinarkaus I., Kruger J., Kallio T., Rocca M.A., Filippi M. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83(5):565-571. (available from: PM:22362918).
33. Stewart N., Simpson S., van der Mei I., Ponsonby A.L., Blizzard L., Dwyer T., Pittas F., Eyles D., Ko P., Taylor B.V. Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012, 79(3):254-260. (available from: PM:22700816).
34. Torkildsen Ø., Wergeland S., Bakke S., Beiske A.G., Bjerve K.S., Hovdal H., Midgard R., Lilleas F., Pedersen T., Bjørnarå B., Dalene F., Kleveland G., Schepel J., Olsen I.C., Myhr K.M. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch. Neurol. 2012, 69(8):1044-1051. (available from: PM:22507886).
35. van Etten E., Gysemans C., Branisteanu D.D., Verstuyf A., Bouillon R., Overbergh L., Mathieu C. Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J. Steroid Biochem. Mol. Biol. 2007, 103(3-5):546-551. (available from: PM:17254771).